Lippoldt Darin sold $1.7M of NBIX
Lippoldt Darin (Chief Legal Officer) sold 10,000 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at an average of $170.15 ($169.56–$170.81, $1.70M total) across 3 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market sale amount, timing, and 10b5-1 status; it informs sentiment but not company guidance or fundamentals.
Market read
Useful for monitoring insider behavior, but unlikely to drive a standalone trading decision without additional corroborating catalysts.
What to watch
Traders should check for any concurrent insider buys/sales by other officers/directors and whether there are subsequent filings that change the narrative.
Background
The article is an SEC Form 4 insider transaction disclosure for Neurocrine Biosciences (NBIX).
Ticker impact
SEC Form 4 shows NBIX COO sold $1.70M of shares (10,000) in late June under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; any effect should be modest and fade unless followed by additional disclosures.
The filing is a routine open-market sale by an officer under a 10b5-1 plan, with no accompanying company-specific operational or financial catalyst in the text.
Market effects
No sector read-through; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerNEUROCRINE BIOSCIENCES INC
Subject of the Form 4 insider transaction disclosure.
- insiderLippoldt Darin
Chief Legal Officer who sold 10,000 NBIX shares for ~$1.70M under a 10b5-1 plan.
